UBE2O CRISPR/Cas9 KO Plasmid (h): sc-410610
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- UBE2O CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UBE2O genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: UBE2O Antibody (2C10): sc-293246
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UBE2O CRISPR/Cas9 KO Plasmid (h) | sc-410610 | 20 µg | $397.00 |
Overview
UBE2O encodes an E2/E3 hybrid ubiquitin-conjugating enzyme that mediates ubiquitin transfer to substrate proteins, linking ubiquitination to proteostasis and protein quality control. It participates in regulation of translation-associated pathways, stress-responsive remodeling of protein complexes, and cell-state transitions by targeting select proteins for ubiquitin-dependent turnover. Through its influence on ubiquitin signaling and stability of key regulators, UBE2O has been studied in contexts including altered proteome homeostasis, metabolic adaptation, and cell cycle or differentiation-associated programs. Dysregulated UBE2O activity and ubiquitination dynamics are frequently explored in cancer and other diseases characterized by disrupted protein degradation and stress responses.
UBE2O CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UBE2O gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UBE2O together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UBE2O open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UBE2O protein expression.
This CRISPR knockout system enables efficient generation of UBE2O-deficient cell models for investigation of UBE2O signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting UBE2O exon(s) critical for UBE2O function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple UBE2O genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by UBE2O CRISPR/Cas9 KO Plasmid (h) and UBE2O CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UBE2O locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by UBE2O HDR Plasmid (h) and UBE2O HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UBE2O homology arms to support homology-directed repair at defined UBE2O target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.